Une initiative de ADFI Alsace

Alimenté par : Claudia (ADFI Alsace), Gaëlle (ADFI), Isabelle, Maïlé Onfray

Cet outil s'appuie sur PubMind

Un accès direct à la littérature scientifique via la base PubMed permettant de faciliter la veille sur les enjeux complexes de la santé mentale et du fait religieux : de la neuroscience des croyances à l'étude des abus spirituels, en passant par la prise en charge des traumatismes et des processus de déconversion.

Dernière synchronisation le 23/06/2026

Thérapies de Conversion

Pratiques visant à modifier l'orientation sexuelle ou l'identité de genre, illégales en France depuis la loi n°2022-92, et leurs effets psychologiques documentés.

500 articles disponibles

conversion therapy
sexual orientation change effort
SOCE harm
gender identity conversion
reparative therapy mental health
ex-gay therapy
conversion practice religious

How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer.

Colorectal liver metastases (CRLM) represent a major determinant of prognosis in patients with metastatic colorectal cancer and account for a substantial proportion of cancer-related mortality worldw…

Thérapies de Conversion
Pérez-Santiago, L., Huntley, P. a. s. c. u. a. l. . D., Sánchez, L. a. r. a. . J. S., Huerta, M., & Dorcaratto, D. (2026). How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer.. Cancers (Basel), 18(3). https://doi.org/10.3390/cancers18030489
02/02/2026 Lire →

Reducing Disparities and Improving Mental Health for Transgender Persons.

This opinion piece primarily targets health and ancillary professionals, but it is also intended to serve as an unbiased guide for policymakers and legislators worldwide. It calls for the protection o…

Thérapies de Conversion
Almeida, O. F. X., & Morgado, P. (2026). Reducing Disparities and Improving Mental Health for Transgender Persons.. Alpha Psychiatry, 27(1), 45278. https://doi.org/10.31083/AP45278
01/02/2026 Lire →

Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.

BACKGROUND: Findings regarding long-term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported. This study was …

Thérapies de Conversion
Ohama, H., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Tsuji, K., Ishikawa, T., Tajiri, K., Tanaka, H., Toyoda, H., Ogawa, C., Nishimura, T., Hatanaka, T., Kakizaki, S., … RELPEC, G. r. o. u. p. . a. n. d. . H. C. C. . 4. 8. . G. r. o. u. p. (2026). Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.. Cancer Med, 15(2), e71640. https://doi.org/10.1002/cam4.71640
01/02/2026 Lire →

The impact of neoadjuvant therapy on postoperative outcomes in patients undergoing hepatectomies for hepatocellular carcinoma.

BACKGROUND: Hepatocellular carcinoma (HCC) treatment is evolving rapidly with systemic/locoregional therapies which increase surgical options. This study explores whether neoadjuvant therapies affect …

Thérapies de Conversion
Yager, S. L., Erol, A., & Wong, L. L. (2026). The impact of neoadjuvant therapy on postoperative outcomes in patients undergoing hepatectomies for hepatocellular carcinoma.. HPB (Oxford), 28(2), 218-224. https://doi.org/10.1016/j.hpb.2025.11.010
01/02/2026 Lire →

Application of hepatic artery interventional therapies in the conversion treatment of unresectable hepatocellular carcinoma: A systematic review and meta-analysis.

BACKGROUND: The conversion therapy aims to transform initially unresectable hepatocellular carcinoma (uHCC) into a resectable state through systemic or locoregional treatment (LRT). However, there is …

Thérapies de Conversion
Zeng, Y., Wang, Z., Lin, S., & Yan, Y. (2026). Application of hepatic artery interventional therapies in the conversion treatment of unresectable hepatocellular carcinoma: A systematic review and meta-analysis.. Am J Surg, 252, 116712. https://doi.org/10.1016/j.amjsurg.2025.116712
01/02/2026 Lire →

Simultaneous versus staged resection for conversion surgery in initially unresectable colorectal liver metastases: a multicenter prospective cohort study.

BACKGROUND: For patients with initially unresectable colorectal liver metastases (IU-CRLM) who achieve resectability through conversion therapy, the choice between simultaneous and staged resection re…

Thérapies de Conversion
Chen, Y., Zhu, J., Xu, P., Zheng, P., Ye, Q., Wang, X., Zhu, D., Zhang, J., Lin, S., Feng, Q., Tang, W., Wang, K., Ren, L., Ye, L., & Xu, J. (2026). Simultaneous versus staged resection for conversion surgery in initially unresectable colorectal liver metastases: a multicenter prospective cohort study.. Int J Surg, 112(2), 3424-3432. https://doi.org/10.1097/JS9.0000000000003982
01/02/2026 Lire →

[Transformation of gastrointestinal surgery diagnosis and treatment models].

In recent years, with the rapid development of medical device and biopharmaceutical technologies, the treatment model of gastric cancer surgery has been undergoing tremendous transformations. From the…

Thérapies de Conversion
Li, Z. Y., Jia, Y. N., & Tang, X. H. (2026). [Transformation of gastrointestinal surgery diagnosis and treatment models].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(1), 10-17. https://doi.org/10.3760/cma.j.cn441530-20251012-00376
25/01/2026 Lire →

Belatacept in Solid Organ Transplantation: Current Kidney Applications, Future Perspectives in Other Organs, and Clinical Implications.

Belatacept, a selective costimulation blocker targeting the CD28-CD80/86 pathway, represents a major innovation in solid organ transplantation immunosuppression. By providing upstream inhibition of T-…

Thérapies de Conversion
Di, M. a. r. i. a. . S., & Provenzani, A. (2026). Belatacept in Solid Organ Transplantation: Current Kidney Applications, Future Perspectives in Other Organs, and Clinical Implications.. Pharmaceuticals (Basel), 19(2). https://doi.org/10.3390/ph19020196
23/01/2026 Lire →

Individualized treatment strategies for primary hepatic neuroendocrine carcinoma: Two case reports and literature review (A CARE-compliant case report).

RATIONALE: Primary hepatic neuroendocrine carcinoma (PHNET) is an exceptionally rare malignancy with limited standardized treatment options.PATIENT CONCERNS: Two patients presented with incidentally d…

Thérapies de Conversion
Hu, H., Chen, K., Xiao, H., & Lan, X. (2026). Individualized treatment strategies for primary hepatic neuroendocrine carcinoma: Two case reports and literature review (A CARE-compliant case report).. Medicine (Baltimore), 105(4), e47242. https://doi.org/10.1097/MD.0000000000047242
23/01/2026 Lire →

Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.

Conversion therapy remains an uncommon strategy for managing unresectable hepatocellular carcinoma (uHCC) due to limited evidence supporting its efficacy. To address this gap, we initiated a prospecti…

Thérapies de Conversion
Zhang, X., Cai, H., Peng, W., Wang, H., Wu, J., Zhu, X., Guo, W., Xie, F., Zhang, Y., Wang, M., Yu, Y., Zhou, Y., Li, C., Shen, J., Liu, C., Yang, Y., Jiang, X., Li, Q., Chen, W., … Wen, T. (2026). Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.. Signal Transduct Target Ther, 11(1), 37. https://doi.org/10.1038/s41392-025-02498-z
22/01/2026 Lire →

Imaging-based prediction of durable benefit in conversion therapy for hepatocellular carcinoma: implications for surgical decision-making.

Thérapies de Conversion
Gou, F. (2026). Imaging-based prediction of durable benefit in conversion therapy for hepatocellular carcinoma: implications for surgical decision-making.. Int J Surg. https://doi.org/10.1097/JS9.0000000000004810
21/01/2026 Lire →

Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma.

BACKGROUND: The criteria for identifying patients with potentially resectable hepatocellular carcinoma (HCC) at the baseline stage have helped identify patients who are more likely to achieve successf…

Thérapies de Conversion
He, T., Xu, B., Yang, Z. Y., Zhou, S. Q., Wang, Z. Y., Wang, L. N., Zhong, C. J., Shi, H. C., Li, H., Hu, B., Zhu, X. D., Shen, Y. H., Gao, Q., Zhou, J., Fan, J., Sun, H. C., & Huang, C. (2026). Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma.. Liver Cancer. https://doi.org/10.1159/000550497
19/01/2026 Lire →